S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
LON:AGY

Allergy Therapeutics Share Forecast, Price & News

GBX 33.50
+0.50 (+1.52 %)
(As of 10/22/2021 12:00 AM ET)
Add
Compare
Today's Range
33
33.90
50-Day Range
28.95
38
52-Week Range
12.40
39
Volume512,012 shs
Average Volume350,852 shs
Market Capitalization£215.00 million
P/E Ratio83.75
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AGY News and Ratings via Email

Sign-up to receive the latest news and ratings for Allergy Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Allergy Therapeutics logo

About Allergy Therapeutics

Allergy Therapeutics plc engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Acarovac MPL, Venomil, Synbiotics, Penicillin Diagnostics, and Peanut. The company also develops allergy vaccines for grass, tree, and house dust mite, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Drug Manufacturers - Major
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Employees
600
Year Founded
N/A

Sales & Book Value

Annual Sales
£84.33 million
Cash Flow
GBX 6.30 per share
Book Value
GBX 7.60 per share

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market Cap
£215.00 million
Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Allergy Therapeutics (LON:AGY) Frequently Asked Questions

What stocks does MarketBeat like better than Allergy Therapeutics?

Wall Street analysts have given Allergy Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Allergy Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Allergy Therapeutics' earnings last quarter?

Allergy Therapeutics plc (LON:AGY) announced its quarterly earnings results on Wednesday, March, 4th. The company reported $2.40 EPS for the quarter.
View Allergy Therapeutics' earnings history
.

How has Allergy Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Allergy Therapeutics' stock was trading at GBX 9.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AGY stock has increased by 262.2% and is now trading at GBX 33.50.
View which stocks have been most impacted by COVID-19
.

Who are Allergy Therapeutics' key executives?

Allergy Therapeutics' management team includes the following people:
  • Mr. Manuel Llobet, CEO & Exec. Director (Age 57, Pay $496.46k)
  • Mr. Nicolas Alexander Ulrich Wykeman, CFO & Exec. Director (Age 56, Pay $284.83k)
  • Ms. Beverly Lees, Group Operations Director
  • Dr. Murray Skinner, Chief Scientific Officer
  • Mr. Santiago Puig, Bus. Devel. Director
  • Ms. Sue Baker, Head of HR
  • Simon Piggott, Head of Clinical Science
  • Alan Bullimore, Head of Communication & Market Devel.
  • Mr. Russell Picket, Group Financial Controller
  • Sara Goldsbrough, Company Sec.

What other stocks do shareholders of Allergy Therapeutics own?

What is Allergy Therapeutics' stock symbol?

Allergy Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "AGY."

How do I buy shares of Allergy Therapeutics?

Shares of AGY and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Allergy Therapeutics' stock price today?

One share of AGY stock can currently be purchased for approximately GBX 33.50.

How much money does Allergy Therapeutics make?

Allergy Therapeutics has a market capitalization of £215.00 million and generates £84.33 million in revenue each year.

How many employees does Allergy Therapeutics have?

Allergy Therapeutics employs 600 workers across the globe.

What is Allergy Therapeutics' official website?

The official website for Allergy Therapeutics is www.allergytherapeutics.com.

Where are Allergy Therapeutics' headquarters?

Allergy Therapeutics is headquartered at Dominion Way, WORTHING, BN14 8SA, United Kingdom.

How can I contact Allergy Therapeutics?

Allergy Therapeutics' mailing address is Dominion Way, WORTHING, BN14 8SA, United Kingdom. The company can be reached via phone at +44-1903-844700.


This page was last updated on 10/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.